Literature DB >> 16810125

Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy.

Tim R Cressey, Prattana Leenasirimakul, Gonzague Jourdain, Yardpiroon Tawon, Pra-Ornsuda Sukrakanchana, Marc Lallemant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16810125     DOI： 10.1097/01.qai.0000221685.90681.1b

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  6 in total

1.  Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.

Authors:  Reshmie Ramautarsing; Jintanat Ananworanich
Journal:  AIDS Res Ther       Date:  2010-06-23       Impact factor: 2.250

2.  Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.

Authors:  Marc Lallemant; Nicole Ngo-Giang-Huong; Gonzague Jourdain; Patrinee Traisaithit; Tim R Cressey; Intira J Collins; Tapnarong Jarupanich; Thammanoon Sukhumanant; Jullapong Achalapong; Prapan Sabsanong; Nantasak Chotivanich; Narong Winiyakul; Surabon Ariyadej; Annop Kanjanasing; Janyaporn Ratanakosol; Jittapol Hemvuttiphan; Karun Kengsakul; Wiroj Wannapira; Veerachai Sittipiyasakul; Witaya Pornkitprasarn; Prateung Liampongsabuddhi; Kenneth McIntosh; Russell B Van Dyke; Lisa M Frenkel; Suporn Koetsawang; Sophie Le Coeur; Siripon Kanchana
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

3.  Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.

Authors:  Jintanat Ananworanich; Meena Gorowara; Anchalee Avihingsanon; Stephen J Kerr; Nadine van Heesch; Chuleeporn Khongpetch; Anuntaya Uanithirat; Andrew Hill; Kiat Ruxrungtham; David M Burger
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

4.  Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.

Authors:  Selwyn J Hurwitz; Ghazia Asif; Nancy M Kivel; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

5.  Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.

Authors:  Selwyn J Hurwitz; Ghazia Asif; Emilie Fromentin; Phillip M Tharnish; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

6.  Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.

Authors:  Thong Phe; Sopheak Thai; Chhunheng Veng; Sopheak Sok; Lutgarde Lynen; Johan van Griensven
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.